Clinical Trial Update: Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial of paricalcitol with gemcitabine and nab-paclitaxel in metastatic pancreatic cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• Paricalcitol (paricalcitol)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Pancreatic Cancer | Phase 1 | Status: TERMINATED